Eduard Shantsila,Gregory Y H Lip
Eduard Shantsila
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung emboli...
Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia [0.03%]
基于血红蛋白的携氧剂Hemospan的潜在应用：可用于治疗下肢严重缺血的血液替代品
Younes Smani
Younes Smani
Hemospan, a novel hemoglobin-based oxygen carrier and plasma expander, is being developed by Sangart Inc for use as a blood substitute and for the treatment of critical limb ischemia. Hemospan is currently undergoing phase III clinical tria...
Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents [0.03%]
诱导离子电流和内皮素途径作为抗心律失常剂的作用靶点
De-Zai Dai,Yin Dai
De-Zai Dai
The development of novel anti-arrhythmic drugs is necessary, specifically agents that do not cause torsades de pointes (Tdp). Ion channelopathy that is involved in mechanisms underlying sudden cardiac death (SCD) includes both ion channels ...
Glucose-6-phosphate dehydrogenase: a novel therapeutic target in cardiovascular diseases [0.03%]
葡萄糖六磷酸脱氢酶：心血管疾病的新型治疗靶点
Sachin A Gupte
Sachin A Gupte
Vascular dysfunction associated with diabetes, heart failure and pulmonary hypertension is the major cause of morbidity and mortality worldwide. Although the causes of vascular dysfunction remain unclear, altered glucose metabolism appears ...
The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells [0.03%]
生长激素和类胰岛素一号生长因子对衰老心血管系统及其祖细胞的影响
Jessica K Devin,Pampee P Young
Jessica K Devin
Aging is a major risk factor for the development of cardiovascular disease. Aging is also associated with a decline in the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis. This axis impacts endothelial and vascular smooth ...
J Ruth Wu-Wong
J Ruth Wu-Wong
Endothelial cells detect physical and chemical changes in the blood vessels, and release various factors to counter these changes to maintain homeostasis. Traditional cardiovascular disease risk factors, such as hypertension, dyslipidemia a...
Bradley A Maron,Jane A Leopold
Bradley A Maron
Hyperaldosteronism is associated with endothelial dysfunction and impaired vascular reactivity in patients with hypertension or congestive heart failure. When present, endothelial dysfunction is an independent predictor of adverse cardiovas...
Hermann A M Mucke
Hermann A M Mucke
Pulmonary arterial hypertension (PAH) is an orphan disease for which no specific pharmacological therapy was available until 1996. Pharmacotherapy for PAH is currently dominated by three endothelin receptor antagonists, bosentan, ambrisenta...
Stephen J Nicholls
Stephen J Nicholls
Residual cardiovascular risk despite lowering LDL-cholesterol has stimulated research to develop strategies that promote the protective properties of HDL-cholesterol. Population and animal studies have suggested that HDL plays an important ...
The development of novel anti-hyperlipidemic drugs: a tough business gets tougher [0.03%]
新型降脂药物的研发：一项艰难的事业愈发艰难
Brian R Krause
Brian R Krause